Netherlands· NL-c709ad26bdbb

Vosevi 200 mg/50 mg/50 mg, filmomhulde tabletten

A sofosbuvir, velpatasvir and voxilaprevir product containing sofosbuvir + velpatasvir + voxilaprevir, registered in Netherlands by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.

ATC J05AP56

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about sofosbuvir + velpatasvir + voxilaprevirAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search sofosbuvir, velpatasvir and voxilaprevir products by name

Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Italyprice
Netherlands
Norwayprice
Polandprice
Spainprice
Switzerlandprice
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

IT Italy$1097.10
CH Switzerland$447.39

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: SOFOSBUVIR + VELPATASVIR + VOXILAPREVIR
Manufacturer: Gilead Sciences Ireland UC
Country: Netherlands (NL)
ATC code: J05AP56
ATC class: Sofosbuvir, velpatasvir and voxilaprevir
Defined daily dose: 0.4 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/17/1223

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Sofosbuvir, velpatasvir and voxilaprevir in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sofosbuvir, velpatasvir and voxilaprevir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Vosevi
Liechtenstein · Vosevi
Norway · Vosevi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/f9e06b66-5ab8-49a3-aa63-bfc1b1933026
GET /v1/drugs/f9e06b66-5ab8-49a3-aa63-bfc1b1933026?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/vosevi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Sofosbuvir, velpatasvir and voxilaprevir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127369",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOVIDON (E 1208)",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "SOFOSBUVIR",
    "VELPATASVIR",
    "VOXILAPREVIR"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/09/16",
  "procedure_number": "EMEA/H/C/004350",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1223",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about sofosbuvir, velpatasvir and voxilaprevir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console